SLC5A2 and myocardial infarction: Moreover, emerging cardioprotective agents, including SGLT2 inhibitors and GLP-1 receptor agonists, have demonstrated beneficial effects in reducing cardiac IR injury during acute myocardial infarction through mechanisms that reduce myocardial infarct size and improve cardiac function and cardiovascular prognosis [27].